Psychedelics biotech startup Entheon Biomedical (CSE:ENBI) (OTCQB:ENTBF) announced the approval by the local Dutch ethics committee for a Phase 1 clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of the psychedelic compound DMT.
DMT is known as the active ingredient in ayahuasca, a ceremonial hallucinogenic concoction traditionally used by indigenous communities in some parts of South America.
